Immunomodulation of FOXP3+ Regulatory T Cells by the Aromatase Inhibitor Letrozole in Breast Cancer Patients
Daniele Generali(University of Trieste), Stephen B. Fox(Peter MacCallum Cancer Centre), Alessandra Bersiga(Istituti Ospitalieri di Cremona), Giovanni Allevi(Istituti Ospitalieri di Cremona), Maria Pia Brizzi(Ospedale San Luigi Gonzaga), Alison H. Banham(Cancer Research UK), Sergio Aguggini(Istituti Ospitalieri di Cremona), Luigi Dogliotti(Aarhus University Hospital), Adrian L. Harris(University of Oxford), Gaynor J. Bates(John Radcliffe Hospital), Manuela Milani(Humanitas University), Alfredo Berruti(Ospedale San Luigi Gonzaga), Simone Bonardi(Istituti Ospitalieri di Cremona), Leticia Campo(University of Oxford), Alberto Bottini(University of Genoa)
Cited by 161
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer
|Journal of Clinical Oncology|2005|1.9k
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
|Clinical Cancer Research|2008|1.5k